CN106220669B - A kind of dialkyl tin complex of the ligand containing acylhydrazone and its preparation method and application - Google Patents
A kind of dialkyl tin complex of the ligand containing acylhydrazone and its preparation method and application Download PDFInfo
- Publication number
- CN106220669B CN106220669B CN201610709360.8A CN201610709360A CN106220669B CN 106220669 B CN106220669 B CN 106220669B CN 201610709360 A CN201610709360 A CN 201610709360A CN 106220669 B CN106220669 B CN 106220669B
- Authority
- CN
- China
- Prior art keywords
- methylbenzyl
- complex
- tert
- tin
- butyl benzoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 title claims description 16
- 239000003446 ligand Substances 0.000 title claims description 11
- -1 tert-butyl benzoyl Chemical group 0.000 claims abstract description 43
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 11
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 11
- 125000006178 methyl benzyl group Chemical group 0.000 claims abstract description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 claims description 36
- 229910052718 tin Inorganic materials 0.000 claims description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 14
- 206010006187 Breast cancer Diseases 0.000 claims description 11
- 208000026310 Breast neoplasm Diseases 0.000 claims description 11
- 201000007270 liver cancer Diseases 0.000 claims description 11
- 208000014018 liver neoplasm Diseases 0.000 claims description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 11
- 239000013078 crystal Substances 0.000 claims description 10
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 9
- 229910021626 Tin(II) chloride Inorganic materials 0.000 claims description 7
- 201000005296 lung carcinoma Diseases 0.000 claims description 7
- OQVSACGODYLLEZ-UHFFFAOYSA-N n-tert-butylbenzohydrazide Chemical compound CC(C)(C)N(N)C(=O)C1=CC=CC=C1 OQVSACGODYLLEZ-UHFFFAOYSA-N 0.000 claims description 7
- 235000011150 stannous chloride Nutrition 0.000 claims description 7
- 239000001119 stannous chloride Substances 0.000 claims description 7
- 238000000902 119Sn nuclear magnetic resonance spectroscopy Methods 0.000 claims description 6
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 claims description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 claims description 6
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- 238000002425 crystallisation Methods 0.000 claims description 6
- 230000008025 crystallization Effects 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 5
- 238000002447 crystallographic data Methods 0.000 claims description 5
- 229940054269 sodium pyruvate Drugs 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 241000254173 Coleoptera Species 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- GZMBSNBBQXLNOJ-UHFFFAOYSA-N n-butylbenzohydrazide Chemical group CCCCN(N)C(=O)C1=CC=CC=C1 GZMBSNBBQXLNOJ-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 230000005311 nuclear magnetism Effects 0.000 claims 1
- BFGWFADODZRUMH-UHFFFAOYSA-N 2-methyl-3-oxoprop-2-enoic acid Chemical class O=C=C(C)C(O)=O BFGWFADODZRUMH-UHFFFAOYSA-N 0.000 abstract description 38
- VRJDPZSIONEOLJ-UHFFFAOYSA-N benzyl(methyl)tin Chemical compound C[Sn]CC1=CC=CC=C1 VRJDPZSIONEOLJ-UHFFFAOYSA-N 0.000 abstract description 36
- 210000004027 cell Anatomy 0.000 description 39
- 230000001093 anti-cancer Effects 0.000 description 13
- 239000003814 drug Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 238000000921 elemental analysis Methods 0.000 description 6
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 201000005249 lung adenocarcinoma Diseases 0.000 description 4
- 239000002262 Schiff base Substances 0.000 description 3
- 150000004753 Schiff bases Chemical class 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 125000002524 organometallic group Chemical group 0.000 description 3
- 238000003556 assay Methods 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 125000000962 organic group Chemical group 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- YTZKOQUCBOVLHL-UHFFFAOYSA-N tert-butylbenzene Chemical compound CC(C)(C)C1=CC=CC=C1 YTZKOQUCBOVLHL-UHFFFAOYSA-N 0.000 description 2
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- FTZIQBGFCYJWKA-UHFFFAOYSA-N 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 FTZIQBGFCYJWKA-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 229910020813 Sn-C Inorganic materials 0.000 description 1
- 229910018732 Sn—C Inorganic materials 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- YAYRGNWWLMLWJE-UHFFFAOYSA-L carboplatin Chemical compound O=C1O[Pt](N)(N)OC(=O)C11CCC1 YAYRGNWWLMLWJE-UHFFFAOYSA-L 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- AYOHIQLKSOJJQH-UHFFFAOYSA-N dibutyltin Chemical compound CCCC[Sn]CCCC AYOHIQLKSOJJQH-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- WDQNIWFZKXZFAY-UHFFFAOYSA-M fentin acetate Chemical compound CC([O-])=O.C1=CC=CC=C1[Sn+](C=1C=CC=CC=1)C1=CC=CC=C1 WDQNIWFZKXZFAY-UHFFFAOYSA-M 0.000 description 1
- NJVOZLGKTAPUTQ-UHFFFAOYSA-M fentin chloride Chemical compound C=1C=CC=CC=1[Sn](C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 NJVOZLGKTAPUTQ-UHFFFAOYSA-M 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000013110 organic ligand Substances 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 150000003606 tin compounds Chemical class 0.000 description 1
- XOLBLPGZBRYERU-UHFFFAOYSA-N tin dioxide Chemical compound O=[Sn]=O XOLBLPGZBRYERU-UHFFFAOYSA-N 0.000 description 1
- 229910001887 tin oxide Inorganic materials 0.000 description 1
- CVNKFOIOZXAFBO-UHFFFAOYSA-J tin(4+);tetrahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[Sn+4] CVNKFOIOZXAFBO-UHFFFAOYSA-J 0.000 description 1
- QHGNHLZPVBIIPX-UHFFFAOYSA-N tin(ii) oxide Chemical compound [Sn]=O QHGNHLZPVBIIPX-UHFFFAOYSA-N 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- 238000001942 tin-119 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/22—Tin compounds
- C07F7/2284—Compounds with one or more Sn-N linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/22—Tin compounds
- C07F7/2296—Purification, stabilisation, isolation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
It is the complex of following structure formula (I) the invention discloses a kind of 2 carbonyl propionic acids to tert-butyl benzoyl hydrazone two to methylbenzyl tin complex, wherein Ph is phenyl, and R is to methylbenzyl.The invention also discloses 2 carbonyl propionic acids to preparation method of the tert-butyl benzoyl hydrazone two to methylbenzyl tin complex and the application in preparing anticancer drug.
Description
Technical field
The present invention relates to a kind of 2- carbonyl propionic acids to tert-butyl benzoyl hydrazone two to methylbenzyl tin complex and its preparation
Method and the 2- carbonyl propionic acids are to tert-butyl benzoyl hydrazone two to methylbenzyl tin complex answering in preparing anticancer drug
With.
Background technology
Organotin is a kind of metallo-organic compound containing Sn-C keys.Researcher just notices before very early
The Anticancer Activity in vitro of organo-tin compound.The research of organotin (IV) antitumor activity of compound can trace back to nineteen twenty-nine.
1967, Kanisawa etc. thought that stannic chloride is invalid to the primary tumor of mouse and rat.But in 1972, Brown had found,
Pass through food or drug administration by injection, triphenyltin acetate Ph3SnOOCCH3It can inhibit the tumour growth of mouse, and triphenyltin chloride
Then cannot.Between 1972 ~ 1977 years, Dutch scholar has studied a large amount of organo-tin compound, but finds no further screening valence
The compound of value.They continue deeper into research, finally found that the tin compound of two organic groups coordination, such as tin-oxide
(R2SnO), tin hydroxide [ SnR2(OH) X ] etc. have antitumor activity, and find out that they all contain or hydrolyze and can generate tin oxygen
Key.1980, Crowe etc. was found that some organo-tin compounds have preferable active anticancer again, anti-about organotin from this
The active research of cancer becomes the another extremely active hot spot after cis-platinum.1989, American National anticancer research institute
(National Cancer Institute) has carried out antitumor activity screening to more than 2,000 kinds of organo-tin compounds, as a result table
Some bright organo-tin compounds have inhibiting effect to P388 lymphocytic leukemias.2002, Gielen et al. was to organic
The activity of tin carboxylate compound has done comprehensive summing up, and many organo-tin compounds are thought after research really has preferably in vitro
Active anticancer.
Studies have shown that the organic group connected on organic tin atom and the ligand for participating in being coordinated decide organo-tin compound
Bioactivity, select some itself have the active organic ligand of good biological in organotin tin atom be coordinated cause
The great interest of people.Acylhydrazone is a kind of Schiff compound made of being modified by hydrazide kind compound, they
It is condensed by aldehydes or ketones and hydrazides, there is the bond type similar with peptide bond in molecule, there is good bioactivity, stronger match
Capability and various coordination mode, and have a wide range of applications in medicine, pesticide, material and analytical reagent etc..Closely
Nian Lai, domestic and international many researchers compare it in terms of bioactivity in depth to be studied, and research finds acylhydrazone class
Compound has the various actives such as anticancer, sterilization, anti-inflammatory.Therefore, acylhydrazone class Schiff ligand is combined with organotin, it is intended to
The stronger noval chemical compound of bioactivity is obtained, the interested research direction of people is become.
Chinese patent CN 102718794A disclose a kind of double acylhydrazone class Schiff stannous phenide complexs and its are making
Standby Antilung gland cancer, colon cancer, leukaemia cell drug in application.
Chinese patent CN 101851251A disclose a kind of acylhydrazone class Schiff ligand dibutyl tin complex and its
Application in the drug for preparing treatment liver cancer, adenocarcinoma of lung, breast cancer, prostate cancer, colon cancer or early young grain leukaemia.
Document (Journal of Organometallic Chemistry, 2014,75:It 83-91) reports, organotin
Acylhydrazone class Schiff base complex is thin to human colon cancer cell (HCT-116), human lung adenocarcinoma cell (A549), human umblilical vein endothelial
Born of the same parents (HUVEC) have compared with strong biological activity, and are better than carboplatin.
Document (Journal of Organometallic Chemistry, 2013,724:It 23-31) reports, series has
Machine tin acylhydrazone class Schiff base complex, organo-tin compound and acylhydrazone class Schiff ligand are respectively to human lung adenocarcinoma cell
(A549), the inhibiting effect of the cancer cells such as human colon cancer cell (HCT-8), people in loop (hl-60).
Document (Bioorganic & Medicinal Chemistry Letters, 2015,25: 4461- 4463)
Report, active anticancer of a variety of acylhydrazone class Schiff ligands to human liver cancer cell (HuH-7) and human lung adenocarcinoma cell (A549).
Document (Journal of Organometallic Chemistry, 2016,804:It 48-58) reports, two hydrocarbon
Base tin acylhydrazone class Schiff base complex is to human lung adenocarcinoma cell (A549), human cervical carcinoma cell (HeLa), human breast cancer cell
(MCF-7) inhibiting effect of cancer cells such as.
It is the experiment proved that the substance with active anticancer, present invention choosing based on acylhydrazone class Schiff organotin complex
It selects and tert-butyl benzoyl hydrazine, Sodium Pyruvate is reacted under certain condition with two pairs of methylbenzyl stannous chloride, synthesis obtains
There is certain inhibitory activity to match human lung carcinoma cell (H460), human liver cancer cell (HepG2) and human breast cancer cell (MCF7)
Object is closed, new approach is provided for exploitation anticancer drug.
Invention content
The first object of the present invention is there is provided a kind of 2- carbonyl propionic acids to tert-butyl benzoyl hydrazone two to methylbenzyl tin
Complex.
The second object of the present invention is to provide above-mentioned 2- carbonyl propionic acids and matches to methylbenzyl tin to tert-butyl benzoyl hydrazone two
Close object preparation method.
The third object of the present invention is to provide above-mentioned 2- carbonyl propionic acids and matches to methylbenzyl tin to tert-butyl benzoyl hydrazone two
Close application of the object in preparing anticancer drug.
A kind of 2- carbonyl propionic acids as the first aspect of the present invention match methylbenzyl tin tert-butyl benzoyl hydrazone two
Object is closed, is the complex of structure formula (I)
(I)
Wherein Ph is phenyl, and R is to methylbenzyl.
The 2- carbonyl propionic acids of the present invention are to tert-butyl benzoyl hydrazone two to methylbenzyl tin complex through elemental analysis, infrared
Spectrum, nuclear magnetic resoance spectrum and X-ray single crystal diffraction structural analysis, it is as a result as follows:
Elemental analysis (C62H76N4O8Sn2):Calculated value:C 59.92, H 6.16, N 4.51;Measured value:C 59.95, H
6.13, N 4.52.
FT-IR (KBr, ν/cm-1): 3666, 3327, 3045, 2960, 2866, 1606, 1510, 1487,
1392, 1325, 1205, 1192, 1163, 1972, 921, 850, 815, 765, 719, 596, 555, 540,
503, 460, 418。
1H NMR (500 MHz, CDCl3, δ/ppm): 7.95 (d, J = 8.2 Hz, 2H), 7.47 (d, J =
8.4 Hz, 2H), 7.29 (d, J = 7.8 Hz, 1H), 7.20 (d, J = 7.8 Hz, 1H), 6.87 (m,
6H), 3.10 (s, 4H), 2.20 (s, 6H), 2.11(s, 3H), 1.38(s, 9H)。
13C NMR (126 MHz, CDCl3, δ/ppm): 174.71, 155.83, 138.48, 135.03,
132.65, 129.27, 129.23, 129.10, 128.40, 127.96, 125.20, 50.89, 35.09, 31.20,
21.24, 20.91, 13.06。
119Sn NMR (187 MHz, CDCl3, δ/ppm): -509.34。
The 2- carbonyl propionic acids of the present invention are crystal structure to methylbenzyl tin complex to tert-butyl benzoyl hydrazone two, brilliant
Body is monoclinic system, space group P2 (1)/c, a=1.82997 (7) nm, b=0.87001 (3) nm, c=1.92944 (7)
Nm, α=γ=90 °, β=90.5960 (10) °, Z=4, V=3.07168 (19) nm3, the Mgm of Dc=1.344-3, m (MoK
α)= 0.867 mm-1, F (000)=1280.
The 2- carbonyl propionic acids of the present invention are structurally characterized in that methylbenzyl tin complex tert-butyl benzoyl hydrazone two:Point
Tin atom is seven coordination distortion pentagonal bipyramid configurations in son.
The 2- carbonyl propionic acids of the present invention have certain heat steady methylbenzyl tin complex tert-butyl benzoyl hydrazone two
Determine range, can be stabilized at 98 DEG C or less.
A kind of 2- carbonyl propionic acids as the second aspect of the present invention match methylbenzyl tin tert-butyl benzoyl hydrazone two
Two pairs of methylbenzyl stannous chloride are added, to tert-butyl benzene first in the preparation method for closing object in the reaction vessel for having nitrogen protection
Hydrazides, Sodium Pyruvate and solvent absolute methanol react 5 ~ 24 h under conditions of temperature is 45 ~ 75 DEG C, cooling, filtering, 20 ~
Solvent volatilization crystallization is controlled under conditions of 35 DEG C, obtains yellow transparent crystal, as 2- carbonyl propionic acids are to tert-butyl benzoyl hydrazone two
To methylbenzyl tin complex.
The present invention 2- carbonyl propionic acids be to the preparation characteristic of methylbenzyl tin complex to tert-butyl benzoyl hydrazone two:From
The relatively easy raw material being easy to get sets out, and without the separation of intermediate, directly obtains complicated molecule, i.e. one kettle way;In this way
Reaction economically and environmentally close friend on advantageously.
In a preferred embodiment of the invention, two pairs of methylbenzyl stannous chloride, to tert-butyl benzoyl hydrazine,
The amount ratio of the substance of Sodium Pyruvate three is 1:(1~1.05):(1.05~1.15).
In a preferred embodiment of the invention, the solvent absolute methanol dosage is every mM of two pairs of methylbenzyls
Stannous chloride adds 15 ~ 35 milliliters.
A kind of 2- carbonyl propionic acids as the third aspect of the present invention match methylbenzyl tin tert-butyl benzoyl hydrazone two
Close application of the object in preparing anticancer drug.
Applicant has carried out in vitro methylbenzyl tin complex tert-butyl benzoyl hydrazone two above-mentioned 2- carbonyl propionic acids
Active anticancer determines research, it is thus identified that 2- carbonyl propionic acids have methylbenzyl tin complex tert-butyl benzoyl hydrazone two certain
Anticancer bioactive, that is to say, that the purposes of above-mentioned complex is the application in preparing anticancer drug, is exactly specifically
Application in preparing anti-human lung cancer, human liver cancer and human breast carcinoma drug.
The 2- carbonyl propionic acids of the present invention are to tert-butyl benzoyl hydrazone two to methylbenzyl tin complex to human lung carcinoma cell, people
Liver cancer cells and human breast cancer cell show good active anticancer, and 2- carbonyl propionic acids of the invention are to tert-butyl benzoyl hydrazone
The features such as two pairs of methylbenzyl tin complex active anticancers are high, at low cost, preparation method is simple, the anticancer drug to develop new carry
New way is supplied.
Description of the drawings
Fig. 1 is for 2- carbonyl propionic acids to tert-butyl benzoyl hydrazone two to the IR spectrograms of methylbenzyl tin complex.
Fig. 2 is for 2- carbonyl propionic acids to tert-butyl benzoyl hydrazone two to methylbenzyl tin complex1H NMR spectras.
Fig. 3 is for 2- carbonyl propionic acids to tert-butyl benzoyl hydrazone two to methylbenzyl tin complex13C NMR spectras.
Fig. 4 is for 2- carbonyl propionic acids to tert-butyl benzoyl hydrazone two to methylbenzyl tin complex119Sn NMR spectras.
Fig. 5 is for 2- carbonyl propionic acids to tert-butyl benzoyl hydrazone two to the crystal structure figure of methylbenzyl tin complex.
Fig. 6 is for 2- carbonyl propionic acids to tert-butyl benzoyl hydrazone two to the TG-DTG curves of methylbenzyl tin complex.
Specific implementation mode
By detailed description below, invention is further described in detail.
Embodiment 1:
Preparation of the 2- carbonyl propionic acids to tert-butyl benzoyl hydrazone two to methylbenzyl tin complex:
0.400g (1.0mmol) two pairs of methylbenzyl dichlorides are added in the 100mL three-necked flasks for having nitrogen protection
Tin, 0.192g (1.0mmol) are to tert-butyl benzoyl hydrazine, 0.121g (1.1mmol) Sodium Pyruvates and 15mL solvents without water beetle
Alcohol reacts 8 h under conditions of temperature is 45 ~ 75 DEG C, cooling, filtering, and solvent volatilization knot is controlled under conditions of 20 ~ 35 DEG C
Crystalline substance, obtains yellow transparent crystal, as 2- carbonyl propionic acids to tert-butyl benzoyl hydrazone two to methylbenzyl tin complex.Yield:
77.4%.Fusing point:98~100℃(dec).
Elemental analysis (C62H76N4O8Sn2):Calculated value:C 59.92, H 6.16, N 4.51;Measured value:C 59.95, H
6.13, N 4.52.
FT-IR (KBr, ν/cm-1): 3666, 3327, 3045, 2960, 2866, 1606, 1510, 1487,
1392, 1325, 1205, 1192, 1163, 1972, 921, 850, 815, 765, 719, 596, 555, 540,
503, 460, 418。
1H NMR (500 MHz, CDCl3, δ/ppm): 7.95 (d, J = 8.2 Hz, 2H), 7.47 (d, J =
8.4 Hz, 2H), 7.29 (d, J = 7.8 Hz, 1H), 7.20 (d, J = 7.8 Hz, 1H), 6.87 (m,
6H), 3.10 (s, 4H), 2.20 (s, 6H), 2.11(s, 3H), 1.38(s, 9H)。
13C NMR (126 MHz, CDCl3, δ/ppm): 174.71, 155.83, 138.48, 135.03,
132.65, 129.27, 129.23, 129.10, 128.40, 127.96, 125.20, 50.89, 35.09, 31.20,
21.24, 20.91, 13.06。
119Sn NMR (187 MHz, CDCl3, δ/ppm): -509.34。
Crystallographic data:Monoclinic system, space group P2 (1)/c, a=1.82997 (7) nm, b=0.87001 (3)
Nm, c=1.92944 (7) nm, α=γ=90 °, β=90.5960 (10) °, Z=4, V=3.07168 (19) nm3, Dc=
1.344 Mg·m-3, m (MoK α)=0.867 mm-1, F (000)=1280.
Embodiment 2:
Preparation of the 2- carbonyl propionic acids to tert-butyl benzoyl hydrazone two to methylbenzyl tin complex:
0.400g (1.0mmol) two pairs of methylbenzyl dichlorides are added in the 100mL three-necked flasks for having nitrogen protection
Tin, 0.192g (1.0mmol) are to tert-butyl benzoyl hydrazine, 0.115g (1.05mmol) Sodium Pyruvates and 35mL solvents without water beetle
Alcohol reacts 5 h under conditions of temperature is 45 ~ 75 DEG C, cooling, filtering, and solvent volatilization knot is controlled under conditions of 20 ~ 35 DEG C
Crystalline substance, obtains yellow transparent crystal, as 2- carbonyl propionic acids to tert-butyl benzoyl hydrazone two to methylbenzyl tin complex.Yield:
78.3%.Fusing point:98~100℃(dec).
Elemental analysis (C62H76N4O8Sn2):Calculated value:C 59.92, H 6.16, N 4.51;Measured value:C 59.95, H
6.13, N 4.52.
FT-IR (KBr, ν/cm-1): 3666, 3327, 3045, 2960, 2866, 1606, 1510, 1487,
1392, 1325, 1205, 1192, 1163, 1972, 921, 850, 815, 765, 719, 596, 555, 540,
503, 460, 418。
1H NMR (500 MHz, CDCl3, δ/ppm): 7.95 (d, J = 8.2 Hz, 2H), 7.47 (d, J =
8.4 Hz, 2H), 7.29 (d, J = 7.8 Hz, 1H), 7.20 (d, J = 7.8 Hz, 1H), 6.87 (m,
6H), 3.10 (s, 4H), 2.20 (s, 6H), 2.11(s, 3H), 1.38(s, 9H)。
13C NMR (126 MHz, CDCl3, δ/ppm): 174.71, 155.83, 138.48, 135.03,
132.65, 129.27, 129.23, 129.10, 128.40, 127.96, 125.20, 50.89, 35.09, 31.20,
21.24, 20.91, 13.06。
119Sn NMR (187 MHz, CDCl3, δ/ppm): -509.34。
Crystallographic data:Monoclinic system, space group P2 (1)/c, a=1.82997 (7) nm, b=0.87001 (3)
Nm, c=1.92944 (7) nm, α=γ=90 °, β=90.5960 (10) °, Z=4, V=3.07168 (19) nm3, Dc=
1.344 Mg·m-3, m (MoK α)=0.867 mm-1, F (000)=1280.
Embodiment 3:
Preparation of the 2- carbonyl propionic acids to tert-butyl benzoyl hydrazone two to methylbenzyl tin complex:
0.400g (1.0mmol) two pairs of methylbenzyl dichlorides are added in the 100mL three-necked flasks for having nitrogen protection
Tin, 0.202g (1.05mmol) are anhydrous to tert-butyl benzoyl hydrazine, 0.126g (1.15mmol) Sodium Pyruvates and 25mL solvents
Methanol reacts 24 h under conditions of temperature is 45 ~ 75 DEG C, cooling, filtering, and solvent volatilization is controlled under conditions of 20 ~ 35 DEG C
Crystallization, obtains yellow transparent crystal, as 2- carbonyl propionic acids to tert-butyl benzoyl hydrazone two to methylbenzyl tin complex.Yield:
76.0%.Fusing point:98~100℃(dec).
Elemental analysis (C62H76N4O8Sn2):Calculated value:C 59.92, H 6.16, N 4.51;Measured value:C 59.95, H
6.13, N 4.52.
FT-IR (KBr, ν/cm-1): 3666, 3327, 3045, 2960, 2866, 1606, 1510, 1487,
1392, 1325, 1205, 1192, 1163, 1972, 921, 850, 815, 765, 719, 596, 555, 540,
503, 460, 418。
1H NMR (500 MHz, CDCl3, δ/ppm): 7.95 (d, J = 8.2 Hz, 2H), 7.47 (d, J =
8.4 Hz, 2H), 7.29 (d, J = 7.8 Hz, 1H), 7.20 (d, J = 7.8 Hz, 1H), 6.87 (m,
6H), 3.10 (s, 4H), 2.20 (s, 6H), 2.11(s, 3H), 1.38(s, 9H)。
13C NMR (126 MHz, CDCl3, δ/ppm): 174.71, 155.83, 138.48, 135.03,
132.65, 129.27, 129.23, 129.10, 128.40, 127.96, 125.20, 50.89, 35.09, 31.20,
21.24, 20.91, 13.06。
119Sn NMR (187 MHz, CDCl3, δ/ppm): -509.34。
Crystallographic data:Monoclinic system, space group P2 (1)/c, a=1.82997 (7) nm, b=0.87001 (3)
Nm, c=1.92944 (7) nm, α=γ=90 °, β=90.5960 (10) °, Z=4, V=3.07168 (19) nm3, Dc=
1.344 Mg·m-3, m (MoK α)=0.867 mm-1, F (000)=1280.
Embodiment 4:
Preparation of the 2- carbonyl propionic acids to tert-butyl benzoyl hydrazone two to methylbenzyl tin complex:
4.000g (10.0mmol) two pairs of methylbenzyl dichlorides are added in the 500mL three-necked flasks for having nitrogen protection
Tin, 1.978g (10.3mmol) are anhydrous to tert-butyl benzoyl hydrazine, 1.210g (11.0mmol) Sodium Pyruvates and 210mL solvents
Methanol reacts 22 h under conditions of temperature is 45 ~ 75 DEG C, cooling, filtering, and solvent volatilization is controlled under conditions of 20 ~ 35 DEG C
Crystallization, obtains yellow transparent crystal, as 2- carbonyl propionic acids to tert-butyl benzoyl hydrazone two to methylbenzyl tin complex.Yield:
71.3%.Fusing point:98~100℃(dec).
Elemental analysis (C62H76N4O8Sn2):Calculated value:C 59.92, H 6.16, N 4.51;Measured value:C 59.95, H
6.13, N 4.52.
FT-IR (KBr, ν/cm-1): 3666, 3327, 3045, 2960, 2866, 1606, 1510, 1487,
1392, 1325, 1205, 1192, 1163, 1972, 921, 850, 815, 765, 719, 596, 555, 540,
503, 460, 418。
1H NMR (500 MHz, CDCl3, δ/ppm): 7.95 (d, J = 8.2 Hz, 2H), 7.47 (d, J =
8.4 Hz, 2H), 7.29 (d, J = 7.8 Hz, 1H), 7.20 (d, J = 7.8 Hz, 1H), 6.87 (m,
6H), 3.10 (s, 4H), 2.20 (s, 6H), 2.11(s, 3H), 1.38(s, 9H)。
13C NMR (126 MHz, CDCl3, δ/ppm): 174.71, 155.83, 138.48, 135.03,
132.65, 129.27, 129.23, 129.10, 128.40, 127.96, 125.20, 50.89, 35.09, 31.20,
21.24, 20.91, 13.06。
119Sn NMR (187 MHz, CDCl3, δ/ppm): -509.34。
Crystallographic data:Monoclinic system, space group P2 (1)/c, a=1.82997 (7) nm, b=0.87001 (3)
Nm, c=1.92944 (7) nm, α=γ=90 °, β=90.5960 (10) °, Z=4, V=3.07168 (19) nm3, Dc=
1.344 Mg·m-3, m (MoK α)=0.867 mm-1, F (000)=1280.
Test example:
The 2- carbonyl propionic acids of the present invention are to tert-butyl benzoyl hydrazone two to methylbenzyl tin complex, Anticancer Activity in vitro
Measurement is realized by MTT experiment method.
MTT analytic approach:
3- (4,5-Dimethylthiazol-2-yl) -2,5-diphenyltetrazolium is restored with metabolism
Based on bromide.Succinate dehydrogenase in living cells mitochondria can make exogenous MTT be reduced to the bluish violet of water-insoluble
Crystallization first a ceremonial jade-ladle, used in libation (Formazan) is simultaneously deposited in cell, and dead cell is without this function.Dimethyl sulfoxide (DMSO) (DMSO) can dissolve cell
In first a ceremonial jade-ladle, used in libation, with microplate reader measure characteristic wavelength optical density, can reflect living cells quantity indirectly.
Using mtt assay come measure embodiment 1 preparation 2- carbonyl propionic acids to tert-butyl benzoyl hydrazone two to methylbenzyl tin
Inhibitory activity of the complex to human lung carcinoma cell (H460), human liver cancer cell (HepG2) and human breast cancer cell (MCF7).
Cell strain and cultivating system:H460, HepG2 and MCF7 cell strain are derived from American tissue incubator (ATCC).With containing
RPMI 1640 (GIBICO companies) culture medium of 10% fetal calf serum, in 5% (volume fraction) CO2, 37 DEG C of saturated humidity incubators
Interior carry out in vitro culture.
Test process:Test liquid (1nM ~ 10 μM) is added separately to according to the concentration gradient of concentration in each hole, often
A concentration sets 6 parallel holes.Experiment is divided into drug study group (the test medicine for being separately added into various concentration), control group (only plus is trained
Nutrient solution and cell are not added with test medicine) and blank group (only plus cultivating medicine, be not added with cell and test medicine).Orifice plate after dosing is set
In 37 DEG C, 5%CO272h is cultivated in incubator.The activity of control drug is measured according to the method for test sample.Cultivating 72h
In orifice plate afterwards, add 40 μ L of MTT (being made into 4mg/mL with D-Hanks buffer solutions) per hole.After placing 4h at 37 DEG C, upper layer is removed
Clear liquid.Add 150 μ L DMSO per hole, vibrate 5min, makes Formazan crystallization dissolvings.Finally, using automatic microplate reader in 570nm
The optical density in each hole is detected at wavelength.
Data processing:Data processing uses 7.0 programs of Graph Pad Prism version, complex IC50Pass through journey
The nonlinear regression model (NLRM) with S-shaped dose response is fitted to obtain in sequence.
It is thin to human lung carcinoma cell (H460), human liver cancer cell (HepG2) and human breast cancer cell (MCF7) with MTT analytic approach
Born of the same parents' strain is analyzed, its IC is measured50Value, the results are shown in Table 1, and conclusion is:From the data in the table, with the 2- carbonyls of the present invention
Propionic acid is used as anticancer drug to tert-butyl benzoyl hydrazone two to methylbenzyl tin complex, to human lung carcinoma cell (H460), people liver
Cancer cell (HepG2) and human breast cancer cell (MCF7) have certain drug effect, can be used as the candidate compound of anticancer drug.
1 2- carbonyl propionic acids of table survey methylbenzyl tin complex anticancer drug external activity tert-butyl benzoyl hydrazone two
Try data.
Human lung cancer | Human liver cancer | Human breast carcinoma | |
Cell strain | H460 | HepG2 | MCF7 |
IC50(μM) | 4.18±0.13 | 1.89±1.55 | 2.41±1.51 |
2- carbonyl propionic acids prepared by remaining embodiment are to tert-butyl benzoyl hydrazone two to methylbenzyl tin complex with mtt assay
It is same to the active anticancer test method of human lung carcinoma cell (H460), human liver cancer cell (HepG2) and human breast cancer cell (MCF7)
Test example, test result and table 1 are essentially identical.
It these are only the preferred embodiment of the present invention and test example, be not intended to restrict the invention, it is clear that the skill of this field
Art personnel can carry out the present invention various changes, modification without departing from the spirit and scope of the present invention.If to the present invention's
These modifications and variations within the scope of the claims of the present invention and its equivalent technology, belong to the protection model of the present invention
It encloses.
Claims (6)
1. a kind of dialkyl tin complex of ligand containing acylhydrazone is the complex of following structure formula (I):
(I)
Wherein Ph is phenyl, and R is to methylbenzyl;The complex (I) is crystal structure, and crystallographic data is as follows:It is single
Oblique system, space group P2 (1)/c, a=1.82997 (7) nm, b=0.87001 (3) nm, c=1.92944 (7) nm, α
=γ=90 °, β=90.5960 (10) °, Z=4, V=3.07168 (19) nm3, the Mgm of Dc=1.344-3, m (MoK α)=
0.867 mm-1, F (000)=1280;Tin atom is seven coordination distortion pentagonal bipyramid configurations in molecule;The complex (I)
Ir data:FT-IR (KBr, ν/cm-1): 3666, 3327, 3045, 2960, 2866, 1606, 1510,
1487, 1392, 1325, 1205, 1192, 1163, 1972, 921, 850, 815, 765, 719, 596, 555,
540, 503, 460, 418;Nuclear-magnetism modal data:1H NMR (500 MHz, CDCl3, δ/ppm): 7.95 (d, J = 8.2
Hz, 2H), 7.47 (d, J = 8.4 Hz, 2H), 7.29 (d, J = 7.8 Hz, 1H), 7.20 (d, J = 7.8
Hz, 1H), 6.87 (m, 6H), 3.10 (s, 4H), 2.20 (s, 6H), 2.11(s, 3H), 1.38(s, 9H);13C NMR (127 MHz, CDCl3, δ/ppm): 174.71, 155.83, 138.48, 135.03, 132.65,
129.27, 129.23, 129.10, 128.40, 127.96, 125.20, 50.89, 35.09, 31.20, 21.24,
20.91, 13.06;119Sn NMR (187 MHz, CDCl3, δ/ppm): -509.34;The complex (I) is at 98 DEG C
It can be stabilized below.
2. the preparation method of the dialkyl tin complex of the ligand described in claim 1 containing acylhydrazone, it is characterized in that there is nitrogen guarantor
In the reaction vessel of shield be added two pairs of methylbenzyl stannous chloride, to tert-butyl benzoyl hydrazine, Sodium Pyruvate and solvent without water beetle
Alcohol reacts 5 ~ 24 h under conditions of temperature is 45 ~ 75 DEG C, and cooling, filtering controls solvent volatilization under conditions of 20 ~ 35 DEG C
Crystallization, obtains yellow transparent crystal, as the dialkyl tin complex of the ligand containing acylhydrazone.
3. preparation method as claimed in claim 2, which is characterized in that two pairs of methylbenzyl stannous chloride, to tertiary butyl
Benzoyl hydrazine, Sodium Pyruvate three substance amount ratio be 1:(1~1.05):(1.05~1.15).
4. preparation method as claimed in claim 2, which is characterized in that the solvent absolute methanol dosage is two pairs every mM
Methylbenzyl stannous chloride adds 15 ~ 35 milliliters.
5. application of the dialkyl tin complex of the ligand containing acylhydrazone described in claim 1 in preparing anticancer drug.
6. the application described in claim 5, wherein the cancer cell is human lung carcinoma cell, human liver cancer cell, human breast cancer cell.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610709360.8A CN106220669B (en) | 2016-08-24 | 2016-08-24 | A kind of dialkyl tin complex of the ligand containing acylhydrazone and its preparation method and application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610709360.8A CN106220669B (en) | 2016-08-24 | 2016-08-24 | A kind of dialkyl tin complex of the ligand containing acylhydrazone and its preparation method and application |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106220669A CN106220669A (en) | 2016-12-14 |
CN106220669B true CN106220669B (en) | 2018-09-07 |
Family
ID=57553604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610709360.8A Active CN106220669B (en) | 2016-08-24 | 2016-08-24 | A kind of dialkyl tin complex of the ligand containing acylhydrazone and its preparation method and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106220669B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3576750A4 (en) | 2017-02-06 | 2021-04-21 | Per Svenningsson | Idoxuridine and its analogs as neuroprotectans for the treatment of parkinsonism |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105384770B (en) * | 2015-11-11 | 2018-03-23 | 衡阳师范学院 | A kind of 2 carbonyl propionic acid salicyloyl hydrazones two are to methyl-benzyl tin complex and its preparation method and application |
-
2016
- 2016-08-24 CN CN201610709360.8A patent/CN106220669B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN106220669A (en) | 2016-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106432323A (en) | 2-carbonyl butyric acid p-methoxy benzoyl hydrazone di-n-butyltin complex and preparation method and application thereof | |
CN106336427B (en) | A kind of 2- carbonyl -2- phenylacetic acid p-nitrophenyl formyl hydrazone two (2,4- dichloro benzyl) tin complex and its preparation method and application | |
CN106220669B (en) | A kind of dialkyl tin complex of the ligand containing acylhydrazone and its preparation method and application | |
CN106366113A (en) | 2-oxo-propionic acid p-toluyl hydrazone di-2, 4-dichlorobenzyltin complex and its preparation method and use | |
CN106336430B (en) | A kind of ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone di-n-butyl tin complex and its preparation method and application | |
CN106220672B (en) | A kind of di-n-butyl tin complex of the ligand containing acylhydrazone and its preparation method and application | |
CN106366119B (en) | A kind of 2- carbonyls -2- phenylacetic acids are to methoxybenzoyl hydrazone di-n-butyl tin complex and its preparation method and application | |
CN106220670B (en) | Two pairs of methylbenzyl tin complexs of one kind and its preparation method and application | |
CN106279261B (en) | A kind of di-n-butyl tin complex and its preparation method and application | |
CN106220678B (en) | A kind of disubstituted benzyl tin complex and its preparation method and application | |
CN106279258B (en) | A kind of dialkyl tin complex and its preparation method and application | |
CN106220676B (en) | A kind of 2- carbonyl propionic acids are to methoxybenzoyl hydrazone Dibenzyltin complex and its preparation method and application | |
CN106336429B (en) | A kind of ALPHA-ketobutyric acid is to toluyl hydrazone stannous phenide complex and its preparation method and application | |
CN106220677B (en) | A kind of acylhydrazone organotin complex and its preparation method and application | |
CN106317105B (en) | A kind of 2- carbonyl -2- phenylacetic acid p-nitrophenyl formyl hydrazone di-n-butyl tin complex and its preparation method and application | |
CN106220675B (en) | A kind of stannous phenide complex of the ligand containing acylhydrazone and its preparation method and application | |
CN106220674B (en) | A kind of Dibenzyltin complex and its preparation method and application | |
CN106366118B (en) | A kind of 2- carbonyl -2- phenylacetic acid is to tert-butyl benzoyl hydrazone stannous phenide complex and its preparation method and application | |
CN106279252B (en) | A kind of 2- carbonyls -3- phenylpropionic acids benzoyl hydrazone di-n-butyl tin complex and its preparation method and application | |
CN106220668B (en) | A kind of 2- carbonyls -3- phenylpropionic acids salicyloyl hydrazone di-n-butyl tin complex and its preparation method and application | |
CN106366120B (en) | A kind of ALPHA-ketobutyric acid is to methoxybenzoyl hydrazone stannous phenide complex and its preparation method and application | |
CN106380480B (en) | A kind of ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide complex and its preparation method and application | |
CN106279260B (en) | A kind of ALPHA-ketobutyric acid salicyloyl hydrazone di-n-butyl tin complex and its preparation method and application | |
CN106279250B (en) | A kind of stannous phenide complex and its preparation method and application | |
CN106380479A (en) | 2-oxopropionic acid p-methoxybenzoyl hydrazone di(2,4-dichlorobenzyl) tin complex and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |